Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 3
Submit an article Journal homepage
161
Views
17
CrossRef citations to date
0
Altmetric
Drug Evaluations

Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1

Patricia Moretto The Margaret and Charles Juravinski Cancer Centre Department of Oncology, 699 Concession Street, Hamilton, ON, L8V 5C2, Canada, USA +1 905 387 9495, ext. 64605; +1 905 575 6326; [email protected]
&
Sébastien J Hotte The Margaret and Charles Juravinski Cancer Centre Department of Oncology, 699 Concession Street, Hamilton, ON, L8V 5C2, Canada, USA +1 905 387 9495, ext. 64605; +1 905 575 6326; [email protected]
, MD MSc (HRM) FRCPC
Pages 311-325 | Published online: 09 May 2009

Bibliography

  • Shankar S, Srivasta RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004;7:139-56
  • Salvesen GS, Duckett CS. IAP proteins: blocking the road to death;s door. Nat Rev Mol Cell Biol 2002;3:401-10
  • Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53
  • Blanc-Brude OP, Mesri M, Wall NR, et al. Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003;9:2683-92
  • Vyas S, Juin P, Hancock D, et al. Differentiation-dependent sensitivity to apoptogenic factors in PC12 cells. J Biol Chem 2004;279:30983-93
  • MacFarlane M, Merrison W, Bratton SB, Cohen GM. Proteasome mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 2002;277:36611-6
  • Thorburn A. Death receptor-induced cell killing. Cell Signal 2004;16:139-44
  • Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-9
  • Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30
  • Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37
  • Sprick MR, Walczak H. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 2004;1644:125-32
  • Mayes PA, El-Deiry WS. The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. Cancer J 2006;12:247-9
  • Willey SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82
  • Ashkenazi A, Dixit VM. Death receptors: signalling and modulation. Science 1998;281:1305-8
  • LeBlanc H, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75
  • Griffith TS, Rauch CT, Smolak PJ, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999;162:2597-605
  • Green DR. Apoptotic pathways, paper wraps stone blunts scissors. Cell 2000;102:1-4
  • Held J, Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 2001;4:243-52
  • Lee SH, Shin MS, Kim HS, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001;20:399-403
  • Chawla-sarkar M, Bae SI, Reu FJ, et al. Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and surviving) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004;m11:915-23
  • Deng Y, Lin Y, Wu X. TRAIL –induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002;16:33-45
  • Rathore N, Matta H, Chaudhary PM. An evolutionary conserved pathway of nuclear factor κB activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of IκBα. J Biol Chem 2004;279:39358-65
  • Aggarwall BB. Nuclear factor-kapaB: the enemy within. Cancer Cell 2004;6:203-8
  • Lei K, Nimnual A, Zong WX, et al. The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol 2002;22:4929-42
  • Lamb JA, Ewen ME. Cyclin D1 and molecular chaperones: implications for tumorigenesis. Cell Cycle 2003;2:525-7
  • Piti RM, Masters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. L Biol Chem 1996;271:12687-90
  • Schneider P. Production of recombinant TRAIL and TRAIL receptors: Fc chimeric proteins. Methods Enzymol 2000;322:325-45
  • Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63
  • Ganten TM, Koschny R, Sykora J, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006;12:2640-6
  • Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer 2006;42:2233-40
  • Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006;55:76-84
  • Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7
  • Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5
  • Hao C, Song JH, Hsi B, et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 2004;64:8502-6
  • Nitsch R, Bechamann I, Deisz RA, et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000;356:827-8
  • Qin JZ, Bacon PE, Chaturvedi V, et al. Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations. Exp Dermatol 2002;11:573-83
  • Nesterov A, Ivashenko Y, Kraft AS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial calls. Oncogene 2002;21:1135-40
  • Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62
  • Volkmann X, Fischer U, Bahr MJ, et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007;46(5):1498-508
  • Mundt B, Wirth T, Zender L, et al. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005;54:1590-6
  • Kayagaki N, Yamaguchi N, Nakayama M, et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999a;162:2639-47
  • Mariani SM, Krammer PH. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol 1998;28:1492-8
  • Nieda M, Nicol A, Koezuka Y, et al. TRAIL expression by activated human CD4 (+) V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001;97:2067-74
  • Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing in immune surveillance against tumor development. J Exp Med 2002;195:161-9
  • Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003;21(18):3526-34
  • Grosse-Wilde A, et al. TRAIL-R deficiency in mice enhances lymph npde metastasis without affecting primary tumor development. J Clin Invest 2008;118(1):100-10
  • Cretney E, Shanker A, Yagita H, et al. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 2006;84:87-98
  • Ashkenazi A, Herbst R. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008;118(6):1979-90
  • Pukac L, Kanakaraj P, Humphreys E, et al. HGS-ETR1, a fully human TRAIL receptor I monoclonal antibody, induces cell death in multiple tumor types in vitro and in vivo. Brit J Cancer 2005;92:1430-41
  • Cretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway [review]. Int J Biochem Cell Biol 2007;39(2):280-6 [Epub 7 Oct 2006]
  • Hotte SJ, Hirte HW, Chen EX et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008;14(11):3450-5
  • Tolcher AW, Mita M, Meropol NJ, et al. Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody with agonist Activity to Tumor Necrosis Factor-Related Apoptosis-Inducing ligand Receptor-1. J Clin Oncol 2007;25(11):1390-6
  • Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-5
  • Lacour S, Hammann A, Wotawa A, et al. Anticancer Agents Sensitize tumor Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Caspase-8 Activation and Apoptosis. Cancer Res 2001;61:1645-51
  • Sheikh MS, BurnsTF, Huang Y, et al. p-53-dependent and independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor. Cancer Res 1998;58:1593-8
  • Wu GS, Burns TF, McDonald ER, et al. Induction of the TRAIL receptor KILLER/DR5 in p-53-dependent apoptosis but not growth arrest. Oncogene 1999;18:6411-8
  • Gibson SB, Oyer R, Spalding AC, et al. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000;20:205-12
  • Keane MM, Ettenberg SA, Nau M, et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59:734-41
  • Bonavida BNC, Jazirehi A, Schiller G, Mitzutami Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics. Int J Oncol 1999;15:794-802
  • Zhang XD, Nguyen T, Thomas WD, et al. Mechanisms of resistance of normal cells to TRAIL-induced apoptosis vary between different cell types. FEBS Lett 2000;482:193-9
  • Griffith TS, Chin WA, Jackson GC, et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-40
  • Algeciras-Schimmich A, Griffith TS, Lynch DH, Paya CV. Cell-cycle dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis. J Immunol 1999;162:5205-11
  • Djerbi M, Screpanti V, Catrina AI, et al. The inhibitor of death receptor signalling. FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999;190:1025-32
  • Medema JP, deJong J, Van Hall, et al. Immune escape ot tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999;190:1033-8
  • Kim K, Fisher MJ, Xu SQ, El-Deiry WS. Molecular determinants of response to TRAIL in killing normal and cancer cells. Clin Cancer Res 2000;6:335-46
  • Zhang XD, Franco A, Myers K, et al. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999;59:2747-53
  • Wang P, Zhang J, Bellail A, et al. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 2007;19(11):2237-46
  • Kim JH, Ajaz M, Lokshin A, Lee YJ. Role of Antiapoptotic Proteins in Tumor Necrosis Factor-related Apoptosis-inducing Ligand and Cisplatin-augmented Apoptosis. Clin Can Res 2003;9:3134-41
  • Ranson M, Dive C, Ward T, et al. A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors [abstract 3059]. J Clin Oncol 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2006;24(20):3059
  • Grossmann D, Kim PJ, Blanc-brude OP, et al. Transgenic expression of surviving in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest 2001;108:991-9
  • Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003;9:931-46
  • Tolcher AW, Antonia S, Lewis LD, et al. A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. 2006;24(20):3014
  • Lu M, Strohecker A, Chen F, et al. Aspirin Sensitizes Cancer Cells to TRAIL–Induced Apoptosis by Reducing Survivin Levels. Clin Cancer Res 2008;14:3168-76
  • Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:800-15
  • Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimetic potentiates TRAIL- and TNFα-mediated cell death. Science 2004;305:1471-74
  • Petrucci E, Paquini L, Petronelli A, et al. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gyne Oncol 2007;105(2):481-92
  • Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41
  • del Peso L, Gonzalez-Garcia M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-68
  • Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-21
  • Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999;274:13085-90
  • Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27
  • Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPs translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005;25:8809-23
  • Qin JZ, Xin H, Sitailo LA, et al. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and Noxa. Cancer Res 2006;66:9636-45
  • Koschny R, Holland H, Sykora J, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Can Res 2007;13:3403-12
  • Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A, Stremmel W, Walczak H.TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007;45(3):649-58
  • Sayers TJ, Brooks AD, Koh CY, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003;102:303-10
  • Saulle E, Petronelli A, Pasquini L, et al. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 2007;12(4):635-55
  • Smith MR, Jin F, Joshi I. Bortezolomib Sentitizes Non-Hodgkin's Lymphoma Cells to Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res 2007;13(18 Suppl):5528-34
  • Georgakis G, Li Y, Humphreys R, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Brit J Haemtol 2005;130:501-10
  • Maddipatla S, Ilzaliturri FJH, Knight J, Czuczman M. Augmented Antitumor Activity agains B-Cell lymphoma by a Combination of Monoclonal Antibodies Targeting TRAIL-R1 and CD20. Clin Cancer Res 2007;13(15):4556-64
  • Belyanskaya L, Marti TM, Hopkins-Donaldson S, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007;6:66
  • Gong J, Yand D, Kohanum S, et al. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther 2005;5(12):2991-3000
  • Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003;15:419-24
  • Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-76
  • Bruey JM, Ducasse C, Bonniaud P, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2000;2:645-52
  • Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c – mediated oligomerization of Apaf – 1 and activation of procaspase – 9 by heat shock protein 90. EMBO J 2000;19:4310-22
  • Beere HM, Wolf BB, Cain K, et al. Heat – shock protein 70 inhibits apoptosis by preventing recruitment of procaspase – 9 to the Apaf – 1 apoptosome. Nat Cell Biol 2000;2:469-75
  • Beere HM. The stress of dying: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004;117(Pt 13):2641-51
  • Georgakis GV, Li Y, Rassidakis GZ, et al. Inhibition of Heat Shock Protein 90 Function by 17-Allylamino-17-Demethoxy-Geldanamycin in Hodgkin's Lymphoma Cells Down-RegulatesAktKinase, Dephosphorylates Extracellular Signal Regulated Kinase, and Induces Cell Cycle Arrest and Cell Death. Clinical Cancer Res 2006;12:584-90
  • Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitor for the treatment of cancer. Cell Cycle 2004;3:779-88
  • Henderson C, Mizzau M, Paroni G, et al. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003;278:12579-89
  • MacFarlane M, Kohlhaas SL, Sutcliffe MJ, et al. TRAIL Receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 2005;65(24):11265-70
  • Fandy TE, Shankar S, Ross DD, et al. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005;7:646-57
  • MacFarlane M, et al. Chronic lymphocytic leukemic cells exhibit apoptotic signalling via TRAIL-R1. Cell Death Differ 2005;12:773-82
  • Earel JK Jr, VanOosten RL, Griffith TS. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res 2006;66(1):499-507
  • Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005;24:4609-23
  • Nawrocki ST, Carew JS, Douglas L, et al. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res 2007;67:6987-94
  • Reddy RM, Yeow WS, Chua A, et al. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade. Apoptosis 2007;12(1):55-71
  • Sonnemann J, Kumar KS, Heesch S, et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 2006;28:755-66
  • Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006;66(13):6785-92
  • Park AY, Seol DW. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 2002;295:515-8
  • Cuello M, Ettenberg SA, Clark AS, et al. Down-regulation of the erbB-2 Receptor by Trastuzumab ( Herceptin) Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand–mediated Apoptosis in Breast and ovarian Cancer Cell Lines that Overexpress erbB-2. Cancer Res 2001;61:4892-900
  • Shrader M, Pino MS, Lashinger L, et al. Gefitinib Reverses TRAIL Resistance in Human Bladder Cancer Cell Lines via Inhibition of Akt-Mediated X-Linked Inhibitor of Apoptosis Protein Expression. Cancer Res 2007;67(4):1430-5
  • Teraishi F, Kagawa S, Watanabe T, et al. ZD1839 (Gefitinib, “Iressa”), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett 2005;579:4069-75
  • Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861-9
  • Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005;280:35217-27
  • Meng XW, Lee SH, Dai H, et al. MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis, a mechanistic basis for sorafenib (BAY43-9006)- induced TRAIL sensitization. JBC 2007;282(41):29831-46
  • Ricci MS, Kim MS, Oqi K, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12(1):66-80
  • Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79(2):329-39
  • Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000;97:1754-9
  • Belka C, Schmid B, Marini P, et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 2001;20:2190-6
  • Marini P, Denzinger S, Schiller D, et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006;25:5145-54
  • Takahashi M, Inanami O, Kubota N, et al. Enhancement of cell death by TNF alpha-related apoptosis-inducing ligand (TRAIL) in human lung carcinoma A549 cells exposed to x rays under hypoxia. J Radiat Res (Tokyo) 2007;48(6):461-8
  • Verbrugge I, Vries E, Tait SWG, et al. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 2007 [Epub ahead of print]
  • Vivo C, Liu W, Broaddus VC. c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 2003;278:25461-7
  • Chang L, Kamata H, Solinas G, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006;124(3):601-13
  • Chow LQ, Eckhardt SG, Gustafson DL, et al. HGS-ETR1, an antibody targeting TRAIL-R1, in combination with advanced solid malignancies. Results of a phase 1 and PK study. Poster presented at ASCO 2006 Annual Meeting, Atlanta, USA
  • Oldenhuis CN, Mom CH, Sleijfer S, et al. A Phase 1 Study with the Agonistic TRAIL-R1 Antibody, Mapatumumab, in Combination with Gemcitabine and Cisplatin. Poster presented at ASCO 2008 Annual Meeting, Chicago, USA
  • Greco FA, Bonomi P, Crawford J, et al, Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIl receptor-1, in patients with advanved non-small cell lung cancer. Lung Cancer 2008, doi:10.1016/j.lungcan.2007.12.011. In press.
  • Younes A, Vose JM, Zelenetz AD, et al. Results of a phase 2 trial of HGS-ETR1(agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL) [abstract 489]. Blood 2005;106:146a
  • Kanzler S, Trarbach T, Heinemann V, et al. Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed or Refractory Colorectal Cancer (CRC). Presented at the EORTC-NCI-AACR International Conference on Molecular targets and Cancer Therapeutics, 30 October-3 November, Paris, France
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
  • Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57
  • Gajewski TF. On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol 2007;25:1305-7
  • Vogler M, Durr K, Jovanovic M, et al. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007;26:248-57
  • Khanbolooki S, Nawrocki ST, Arumugam T, et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006;5:2251-60
  • Cheng J, Hylander BL, Baer MR, et al. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 2006;5:1844-53
  • Zhu H, Guo W, Zhang L, et al. Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther 2005;4:393-7
  • Yang LQ, Fang DC, Wang RQ, et al. Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol 2004;10:22-5
  • Zhang XD, Borrow JM, Zhang XY, et al. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003;22:2869-81
  • Chawla-Sarkar M, Bae SI, Reu FJ, et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004;11:915-23
  • Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002;21:2283-94
  • Kandasamy K, Srivastava RK. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 2002;62:4929-37
  • Hopkins-Donaldson S, Bodmer JL, Bourloud KB, et al. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol 2000;35:608-11
  • Han J, Goldstein LA, Gastman BR, et al. Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells. Leukemia 2004;18:1671-80
  • de Vries EGE, de Jong S. Exploiting the apoptotic route for cancer treatment: a single hit will rarely result in a home run. J Clin Oncol 2008;26:5151-3
  • Tolcher AW, Mita A, Lewis LD, et al. Phase I and pharmacokinetic study of YM155, a small molecule inhibitor of survivin. J Clin Oncol 2008;26:5198-203
  • Dyer MJS, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 2007;25:4505-6
  • Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.